Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients
暂无分享,去创建一个
A. Zolopa | J. Gallant | C. Cohen | D. Wohl | E. Dejesus | M. Rhee | A. Mills | H. Liu | A Zolopa | J Gallant | P Sax | J Szwarcberg | P. Sax